Ocugen (OCGN) Enterprise Value (2014 - 2026)
Ocugen's (OCGN) quarterly Enterprise Value came in at -$37.8 million in Q1 2025, down 43.32% YoY from -$66.7 million in Q1 2024, and down 140.81% on a QoQ basis from -$15.7 million in Q2 2024.
Ocugen (OCGN) Enterprise Value (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 12 years of Enterprise Value data on file, last reported at -$37.8 million in Q1 2025.
- Quarterly Enterprise Value fell 43.32% year-over-year to -$37.8 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was -$37.8 million (down 43.32% YoY) and the FY2023 annual result came in at -$39.5 million, up 56.6% from the prior year.
- Enterprise Value slipped to -$37.8 million in Q1 2025, from -$15.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$15.7 million in Q2 2024 to a low of -$129.8 million in Q1 2022.
- A 5-year average of -$75.7 million and a median of -$76.7 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value slumped 1459.04% — and 2024, when it jumped 77.76%.
- Tracing OCGN's Enterprise Value over 5 years: stood at -$95.0 million in 2021, then climbed by 4.24% to -$90.9 million in 2022, then jumped by 56.6% to -$39.5 million in 2023, then soared by 60.22% to -$15.7 million in 2024, then slumped by 140.81% to -$37.8 million in 2025.
- The last three Enterprise Value figures came in at -$37.8 million (Q1 2025), -$15.7 million (Q2 2024), and -$26.4 million (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | -100.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -100.10 Mn |
| Dec 31, 2025 | -18.57 Mn |
| Jun 30, 2025 | -27.01 Mn |
| Mar 31, 2025 | -37.80 Mn |
| Jun 30, 2024 | -15.70 Mn |
| Mar 31, 2024 | -26.38 Mn |
| Dec 31, 2023 | -39.46 Mn |
| Sep 30, 2023 | -53.48 Mn |
| Jun 30, 2023 | -70.58 Mn |
| Mar 31, 2023 | -76.72 Mn |
| Dec 31, 2022 | -90.93 Mn |
| Sep 30, 2022 | -101.60 Mn |
| Jun 30, 2022 | -115.01 Mn |
| Mar 31, 2022 | -129.77 Mn |
| Dec 31, 2021 | -94.96 Mn |
| Sep 30, 2021 | -112.34 Mn |
| Jun 30, 2021 | -120.63 Mn |
| Mar 31, 2021 | -49.78 Mn |
| Dec 31, 2020 | -24.04 Mn |
| Sep 30, 2020 | -19.11 Mn |